Trade

with

Arqule Inc
(NASDAQ: ARQL)
AdChoices
1.18
+0.01
+0.85%
After Hours :
-
-
-

Open

1.15

Previous Close

1.17

Volume (Avg)

18.00k (209.17k)

Day's Range

1.14-1.18

52Wk Range

1.04-2.92

Market Cap.

73.45M

Dividend Rate ( Yield )

-

Beta

1.54

Shares Outstanding

62.77M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 15.91M

    • Net Income

    • -24.60M

    • Market Cap.

    • 73.45M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -223.97

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.54

    • Forward P/E

    • -2.17

    • Price/Sales

    • 6.43

    • Price/Book Value

    • 1.50

    • Price/Cash flow

    • -2.23

      • EBITDA

      • -23.70M

      • Return on Capital %

      • -26.17

      • Return on Equity %

      • -42.53

      • Return on Assets %

      • -26.17

      • Book Value/Share

      • 0.78

      • Shares Outstanding

      • 62.77M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 5.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.67

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -34.60

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 2.39

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -223.97

            • 39.38

            • Net Profit Margin

            • -223.97

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -90.70

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -90.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.05

              • 2.92

              • Quick Ratio

              • 2.99

              • 2.35

              • Interest Coverage

              • -653.33

              • 38.02

              • Leverage Ratio

              • 1.64

              • 2.21

              • Book Value/Share

              • 0.78

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.82

                • 277.78

                • P/E Ratio 5-Year High

                • -20.40

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.55

                • 124.82

                • Price/Sales Ratio

                • 6.31

                • 9.35

                • Price/Book Value

                • 1.47

                • 8.50

                • Price/Cash Flow Ratio

                • -2.23

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -42.53

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -26.17

                    (-16.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -41.30

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.12

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -25.13M
                  Operating Margin
                  -157.89
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -2.23
                  Ownership

                  Institutional Ownership

                  52.95%

                  Top 10 Institutions

                  39.17%

                  Mutual Fund Ownership

                  10.31%

                  Float

                  89.24%

                  5% / Insider Ownership

                  1.86%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Small Cap Stock Fund

                  •  

                    1,334,615

                  • 12.14

                  • 2.13

                  • Biotech Growth Trust Plc

                  •  

                    1,297,400

                  • 0.00

                  • 2.07

                  • Vanguard Extended Market Index Fund

                  •  

                    966,590

                  • 1.60

                  • 1.54

                  • Vanguard Total Stock Mkt Idx

                  •  

                    938,558

                  • 0.00

                  • 1.50

                  • Vanguard Instl Total Stock Market Index

                  •  

                    426,641

                  • 0.00

                  • 0.68

                  • Bridgeway Ultra Small Company Market

                  •  

                    190,000

                  • -44.12

                  • 0.30

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    171,131

                  • 0.00

                  • 0.27

                  • iShares Micro-Cap

                  •  

                    166,122

                  • 0.84

                  • 0.27

                  • TFS Market Neutral Fund

                  •  

                    141,880

                  • -58.71

                  • 0.23

                  • Royce Value Trust

                  •  

                    130,000

                  • 0.00

                  • 0.21

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Orbimed Advisors, LLC

                  •  

                    5,702,000

                  • 0.00%

                  • 9.08

                  • Arnhold & S. Bleichroeder Advisers, LLC

                  •  

                    2,843,599

                  • 0.00%

                  • 4.53

                  • NEA Management Company, LLC

                  •  

                    2,520,316

                  • 0.00%

                  • 4.01

                  • Vanguard Group, Inc.

                  •  

                    2,329,735

                  • -14.35%

                  • 3.71

                  • BlackRock Fund Advisors

                  •  

                    1,888,324

                  • -22.10%

                  • 3.01

                  • Fidelity Management and Research Company

                  •  

                    1,343,907

                  • +48.52%

                  • 2.14

                  • OrbiMed Advisor LLC

                  •  

                    1,297,400

                  • 0.00%

                  • 2.07

                  • Farallon Capital Management, L.L.C.

                  •  

                    1,258,732

                  • 0.00%

                  • 2.01

                  • Renaissance Technologies Corp

                  •  

                    1,102,168

                  • +319.74%

                  • 1.76

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  ArQule, Inc., was organized as a Delaware corporation in 1993 in Delaware. The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQul...moree Kinase Inhibitor Platform (“AKIP​TM”) to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. Its product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase. C-Met is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug thera...morepies. The Company and its partners, Daiichi Sankyo Co., Ltd. (‘Daiichi Sankyo’) and Kyowa Hakko Kirin Co., Ltd. (‘Kyowa Hakko Kirin’), are implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications The Company has licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. Its proprietary pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The advanced candidates in this pipeline are ARQ 087, an inhibitor of fibroblast growth factor receptor, ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, all of which are in Phase 1 clinical testing. Its drug discovery efforts are engaged mainly on AKIP™, which it is using to generate compounds designed to inhibit kinases without competing with adenosine triphosphate (‘ATP’) for binding to the target kinase, as well as other types of kinase inhibitors. ATP is a chemical found in all living cells and is the energy source involved in a variety of physiological processes. The Company faces competition from pharmaceutical companies, biotechnology companies and academic and research organizations. The Company’s product candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA in the United States and by comparable authorities in other countries.lessless

                  Key People

                  Paolo Pucci

                  Director/CEO

                  Patrick J. Zenner

                  Chairman of the Board/Director

                  Robert J. Weiskopf

                  Chief Accounting Officer/Vice President, Divisional/Controller/Treasurer

                  Dr. Ronald M. Lindsay, PhD

                  Director

                  William G. Messenger,D.Min.

                  Director

                  • Arqule Inc

                  • 19 Presidential Way

                  • Woburn, MA 01801

                  • USA.Map

                  • Phone: +1 781 994-0300

                  • Fax: +1 781 376-6019

                  • arqule.com

                  Incorporated

                  1993

                  Employees

                  40

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: